473 related articles for article (PubMed ID: 18559580)
1. The development of phase I cancer trial methodologies: the use of pharmacokinetic and pharmacodynamic end points sets the scene for phase 0 cancer clinical trials.
Calvert AH; Plummer R
Clin Cancer Res; 2008 Jun; 14(12):3664-9. PubMed ID: 18559580
[TBL] [Abstract][Full Text] [Related]
2. A clinical development paradigm for cancer vaccines and related biologics.
Hoos A; Parmiani G; Hege K; Sznol M; Loibner H; Eggermont A; Urba W; Blumenstein B; Sacks N; Keilholz U; Nichol G;
J Immunother; 2007 Jan; 30(1):1-15. PubMed ID: 17198079
[TBL] [Abstract][Full Text] [Related]
3. Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.
El-Maraghi RH; Eisenhauer EA
J Clin Oncol; 2008 Mar; 26(8):1346-54. PubMed ID: 18285606
[TBL] [Abstract][Full Text] [Related]
4. Dose escalation trial designs based on a molecularly targeted endpoint.
Hunsberger S; Rubinstein LV; Dancey J; Korn EL
Stat Med; 2005 Jul; 24(14):2171-81. PubMed ID: 15909289
[TBL] [Abstract][Full Text] [Related]
5. Novel designs and end points for phase II clinical trials.
Adjei AA; Christian M; Ivy P
Clin Cancer Res; 2009 Mar; 15(6):1866-72. PubMed ID: 19276272
[TBL] [Abstract][Full Text] [Related]
6. Phase II clinical trials in oncology: are we hitting the target?
Ang MK; Tan SB; Lim WT
Expert Rev Anticancer Ther; 2010 Mar; 10(3):427-38. PubMed ID: 20214523
[TBL] [Abstract][Full Text] [Related]
7. Pharmacologically based phase I trials in cancer chemotherapy.
Newell DR
Hematol Oncol Clin North Am; 1994 Apr; 8(2):257-75. PubMed ID: 8040140
[TBL] [Abstract][Full Text] [Related]
8. [Methodological approaches of clinical studies with targeted therapies].
Penel N; Saleron J; Lansiaux A; Clisant S; Adenis A; Fournier C; Duhamel A; Bonneterre J
Bull Cancer; 2008 Feb; 95(2):185-90. PubMed ID: 18304903
[TBL] [Abstract][Full Text] [Related]
9. Clinical trial designs for multiple myeloma.
Hoering A; Crowley J
Clin Adv Hematol Oncol; 2007 Apr; 5(4):309-16. PubMed ID: 17607290
[TBL] [Abstract][Full Text] [Related]
10. Assessing tumor-related signs and symptoms to support cancer drug approval.
Williams G; Pazdur R; Temple R
J Biopharm Stat; 2004 Feb; 14(1):5-21. PubMed ID: 15027497
[TBL] [Abstract][Full Text] [Related]
11. Phase 0 clinical trials in cancer drug development: from FDA guidance to clinical practice.
Kinders R; Parchment RE; Ji J; Kummar S; Murgo AJ; Gutierrez M; Collins J; Rubinstein L; Pickeral O; Steinberg SM; Yang S; Hollingshead M; Chen A; Helman L; Wiltrout R; Simpson M; Tomaszewski JE; Doroshow JH
Mol Interv; 2007 Dec; 7(6):325-34. PubMed ID: 18199854
[TBL] [Abstract][Full Text] [Related]
12. Designs for single- or multiple-agent phase I trials.
Conaway MR; Dunbar S; Peddada SD
Biometrics; 2004 Sep; 60(3):661-9. PubMed ID: 15339288
[TBL] [Abstract][Full Text] [Related]
13. New paradigm in dose-finding trials: patient-specific dosing and beyond phase I.
Rogatko A; Babb JS; Tighiouart M; Khuri FR; Hudes G
Clin Cancer Res; 2005 Aug; 11(15):5342-6. PubMed ID: 16061846
[TBL] [Abstract][Full Text] [Related]
14. 'No risk, no fun': challenges for the oncology phase I clinical trial time-performance.
Verweij J
Eur J Cancer; 2008 Nov; 44(17):2600-7. PubMed ID: 18951015
[TBL] [Abstract][Full Text] [Related]
15. New phase I trial methodology.
Mani S; Ratain MJ
Semin Oncol; 1997 Apr; 24(2):253-61. PubMed ID: 9129693
[TBL] [Abstract][Full Text] [Related]
16. Proposal for standardized definitions for efficacy end points in adjuvant breast cancer trials: the STEEP system.
Hudis CA; Barlow WE; Costantino JP; Gray RJ; Pritchard KI; Chapman JA; Sparano JA; Hunsberger S; Enos RA; Gelber RD; Zujewski JA
J Clin Oncol; 2007 May; 25(15):2127-32. PubMed ID: 17513820
[TBL] [Abstract][Full Text] [Related]
17. End points in cancer clinical trials and the drug approval process.
Schilsky RL
Clin Cancer Res; 2002 Apr; 8(4):935-8. PubMed ID: 11948095
[TBL] [Abstract][Full Text] [Related]
18. [Early clinical trial of antineoplastic agents--recent perspectives of pharmacological analysis in phase I study].
Sasaki Y
Gan To Kagaku Ryoho; 2001 Mar; 28(3):411-4. PubMed ID: 11265416
[TBL] [Abstract][Full Text] [Related]
19. Optimising the design of phase II oncology trials: the importance of randomisation.
Ratain MJ; Sargent DJ
Eur J Cancer; 2009 Jan; 45(2):275-80. PubMed ID: 19059773
[TBL] [Abstract][Full Text] [Related]
20. The Cancer Research UK experience of pre-clinical toxicology studies to support early clinical trials with novel cancer therapies.
Newell DR; Silvester J; McDowell C; Burtles SS;
Eur J Cancer; 2004 Apr; 40(6):899-906. PubMed ID: 15120045
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
